Amador Bioscience vs ICON plc

Auto-generated comparison by BioBM Editorial AI. This page highlights available profile evidence side by side and avoids drawing conclusions from missing fields.

Markdown mirror: /api/markdown/compare/amadorbioscience/iconplc

Category	Amador Bioscience	ICON plc
Listed site	cro	cro
Summary	Amador Bioscience provides bioanalysis and biomarker services, including LCMS, immunoassays, flow cytometry, and immunogenicity testing, alongside clinical pharmacology modeling and regulatory affairs support. Its labs are GLP compliant, and its teams work across the US, China, and Europe.	ICON is a global clinical research organization providing full-service drug development and clinical trial solutions across early phase through post-marketing, including clinical operations, bioanalytical labs, cardiac safety, medical imaging, and regulatory affairs.
Services	Bioanalysis Ligand-Binding Bioanalysis (Large Molecule) LC-MS Bioanalysis (Small Molecule) Immunogenicity Assays (ADA / NAb) Flow Cytometry Services Biomarker Assays Biostatistics & Statistical Programming Translational Research Regulatory Affairs Clinical Trial Services Clinical Operations Phase IV / Post-Marketing	Phase I Clinical Trials Phase II Clinical Trials Phase III Clinical Trials Phase IV / Post-Marketing Clinical Operations Clinical Trial Services Clinical Imaging Core Lab Central Laboratory Services Data Management & eClinical Biostatistics & Statistical Programming Medical Writing Pharmacovigilance & Drug Safety Regulatory Affairs US FDA Regulatory Strategy EU EMA Regulatory Strategy Flow Cytometry Services Bioanalysis Translational Research Biomarker Assays Immunogenicity Assays (ADA / NAb) Ligand-Binding Bioanalysis (Large Molecule) LC-MS Bioanalysis (Small Molecule) Cardiovascular & Metabolic Specialty Services CNS Specialty Services Oncology Specialty Services Immunology & Inflammation Services Companion Diagnostics Development Japan PMDA Regulatory Strategy China NMPA Regulatory Strategy
Modalities	Antibody-Drug Conjugate (ADC) Oligonucleotide Peptide Small Molecule Cell Therapy Gene Therapy mRNA Vaccine Biologics (Other)	Small Molecule Biologics (Monoclonal Antibodies) Biologics (Other) Cell Therapy Gene Therapy Vaccine
Indications	Data not yet provided.	Cardiovascular Neurology Immunology Oncology Infectious Disease Metabolic Rare Disease Women's Health Ophthalmology
Locations	California, California, United States Maryland, Maryland, United States Michigan, Michigan, United States Belgium, Belgium Hangzhou, Hangzhou, China Shanghai, Shanghai, China Beijing, Beijing, China	Headquarters, Dublin, Ireland Belgium, Belgium, Belgium Bulgaria, Bulgaria, Bulgaria Germany, Germany, Germany Hungary, Hungary, Hungary Italy, Italy, Italy Netherlands, Netherlands, Netherlands Poland, Poland, Poland Romania, Romania, Romania Slovakia, Slovakia, Slovakia South Africa, South Africa, South Africa Spain, Spain, Spain Türkiye, Türkiye, Türkiye United Kingdom, United Kingdom, United Kingdom Australia, Australia, Australia China, China, China India, India, India Japan, Japan, Japan Korea, Korea, Korea Malaysia, Malaysia, Malaysia Taiwan, Taiwan, Taiwan Argentina, Argentina, Argentina Brazil, Brazil, Brazil Chile, Chile, Chile Colombia, Colombia, Colombia Mexico, Mexico, Mexico Belgium, Belgium, Belgium Bulgaria, Bulgaria, Bulgaria Germany, Germany, Germany Hungary, Hungary, Hungary Italy, Italy, Italy Netherlands, Netherlands, Netherlands Poland, Poland, Poland Romania, Romania, Romania Slovakia, Slovakia, Slovakia South Africa, South Africa, South Africa Spain, Spain, Spain Türkiye, Türkiye, Türkiye United Kingdom, United Kingdom, United Kingdom Australia, Australia, Australia China, China, China India, India, India Japan, Japan, Japan Korea, Korea, Korea Malaysia, Malaysia, Malaysia Taiwan, Taiwan, Taiwan Argentina, Argentina, Argentina Brazil, Brazil, Brazil Chile, Chile, Chile Colombia, Colombia, Colombia Mexico, Mexico, Mexico United States, United States, United States
Certifications	Data not yet provided.	Data not yet provided.
Reviews	Review summary appears after site-level review signal gate opens.	Review summary appears after site-level review signal gate opens.